D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Director Howard G. Welgus of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) sold 10,000 shares of common stock on August 1, 2025, for approximately $142,982. The sales were executed at a weighted average price of $14.2982, with individual transactions ranging from $14.14 to $14.55. The stock, which InvestingPro analysis suggests is currently undervalued, has delivered an impressive 68.5% return over the past year, bringing the company’s market capitalization to $1.81 billion.
Welgus also exercised options to acquire 10,000 shares of Arcutis Biotherapeutics common stock at strike prices of $0.5802 and $1.6806.
The transactions were executed under a pre-arranged 10b5-1 trading plan adopted by Welgus on March 11, 2025, with a plan end date of May 29, 2026. Following the reported transactions, Welgus directly owns 100,206 shares of Arcutis Biotherapeutics.
In other recent news, Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ZORYVE® topical foam 0.3% for the treatment of plaque psoriasis on the scalp and body in adults and children aged 12 and older. This marks the fifth FDA approval for ZORYVE in less than three years, broadening treatment options for nearly 9 million Americans with plaque psoriasis. H.C. Wainwright analysts reiterated their Buy rating with a $19 price target following this FDA approval, emphasizing the foam’s versatility, especially for use in hair-bearing areas. Guggenheim also maintained a Buy rating with a $29 price target, citing growth in prescriptions for the Zoryve product line. Total (EPA:TTEF) prescriptions for the Zoryve franchise reached 16,289, with notable increases in both foam and cream prescriptions. Morgan Stanley (NYSE:MS) has assumed coverage of Arcutis Biotherapeutics with an Overweight rating and a $20 price target, focusing on Zoryve’s market share gains in the non-steroidal topical dermatology segment. Additionally, H.C. Wainwright highlighted the strength of Zoryve cream’s open-label extension study data, noting its potential for long-term use in various age groups. The firm expressed confidence in the upcoming Prescription Drug User Fee Act (PDUFA) decision for Zoryve cream 0.05%, scheduled for October 13.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.